Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04421027 · ClinicalTrials.gov registry record · Phase 3
A Study of Baricitinib (LY3009104) in Participants With COVID-19
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,525
- Enrollment target
NCT04421027 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 1,525 participants.
The verdict
NCT04421027, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,525 participants
- Enrollment target
Study Summary
The reason for this study is to see if the study drug baricitinib is effective in hospitalized participants with COVID-19.
Interventions
- DRUG Placebo
- DRUG Baricitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,525 participants |
| Start Date | 2020-06-12 |
| Est. Completion | 2021-06-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04421027
The ClinicalTrials.gov registry entry for NCT04421027 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,525 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04421027 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04421027 about?
NCT04421027 is a clinical study titled "A Study of Baricitinib (LY3009104) in Participants With COVID-19". The reason for this study is to see if the study drug baricitinib is effective in hospitalized participants with COVID-19.
What is the current status of trial NCT04421027?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,525 participants. The study started on 2020-06-12. Estimated completion is 2021-06-10.
What interventions are being tested in trial NCT04421027?
The interventions under investigation include: Placebo (DRUG), Baricitinib (DRUG).
Who is sponsoring clinical trial NCT04421027?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.